Corxel Pharmaceuticals closed a large financing to advance an oral GLP‑1 candidate into global phase 2/3 development for obesity and metabolic indications. The Series D financing, reported at $287 million, will fund phase 2/3 studies and expansion of regulatory and commercial planning outside China. Investors and company communications indicate Corxel licensed the oral GLP‑1 from Vincentage in 2024 and believes the molecule can match injectable GLP‑1 efficacy. The capital raise comes amid intense funding for obesity therapeutics and follows multiple high‑profile rounds for competitors seeking oral formulations. What happened: Corxel secured substantial growth capital to accelerate clinical development and global regulatory strategy. Sources: BioCentury financing notes and company release. Clinical context: oral GLP‑1 programs aim to match injectable efficacy while improving convenience and payer access.